Total Funding
58
62
Total FundingDebt Financing raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
47784
Sollis Therapeutics is a pharmaceutical company developing non-opioid analgesic solutions.
- Bryan Jones: COOPast Role: Sorrento Therapeutics, Vice President Operations
Alex Dinello: President & CEOPast Role: Kyphon, Vice President, Research&Development
About the Company
Sollis Therapeutics is a clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics. Sollis’ first product is an extended-release combination analgesic and anti-inflammatory drug designed for local delivery for the treatment of sciatica and other neuropathic pain syndromes.
The company was founded in 2017
and is headquartered in Columbus, Ohio.
